Patents by Inventor Yadira Lobaina Mato

Yadira Lobaina Mato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200297840
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 24, 2020
    Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín AGUIAR SANTIAGO, Sonia GONZALEZ BLANCO, Jorge VALDES HERNANDEZ, Mariela VAZQUEZ CASTILLO
  • Publication number: 20120308615
    Abstract: The present invention is related with the field of the therapeutic immunization, specifically with the employment of a new formulation of antigens of the Hepatitis B Virus (HBV) for the cellular stimulation. The formulation is formed by the surface antigens (HBsAg) precipitated in suspension and the nucleocapsid (HBcAg) of the HBV. The formulation contains these antigens like suspended particles of sizes less than 500 nm and higher than 500 nm, in a mixture where the proportion among the particles of the mentioned sizes is among 50%-50% and 80%-20%, respectively. The selection of a range of sizes of particles allows that the levels of stimulation of several cellular types are maximized. Additionally, a cellular stimulation method is described with this formulation, and the later passive immunization of patients with chronic Hepatitis B, based on the maximum stimulation in vivo or in vitro using heterologous or autologous cells (dendritic cells, B cells and macrophages).
    Type: Application
    Filed: September 28, 2010
    Publication date: December 6, 2012
    Inventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Dunia Hernández Inguanzo, Heidy Trujillo Pérez, Freya de los Milagros Freyre Almeida, Verena Lucila Muzio González, Eduardo Pénton Arias, Sonia Gonzalez Blanco, Raimundo Ubieta Gómez, Gerardo Enrique Guillén Nieto, Luis Saturnino Herrera Martinez
  • Publication number: 20070275012
    Abstract: The present invention is related with the field of therapeutic vaccines against pathogens causing chronic diseases. It comprises the use in therapy of formulations containing the Hepatitis B surface antigen (HBsAg) as the main compound. The HBsAg is produced as a recombinant product in Picchia pastoris. The formulations of the present invention also comprise the combination of the Hepatitis B surface antigen and other coadministered antigens. The resulting formulations are able to generate potent lymphoprolipherative and cytotoxic responses apart from a remarkable response of specific antibodies, which make them very effective in the treatment of such diseases.
    Type: Application
    Filed: October 20, 2004
    Publication date: November 29, 2007
    Inventors: Julio Aguilar Rubido, Enrique Iglesias Perez, Yadira Lobaina Mato, Daymir Garcia Gonzalez, Verena Muzio Gonzalez, Gerardo Guillen Nieto, Nelson Acosta Rivero, Raimundo Ubieta Gomez, Julio Alvarez Obregon, Santiago Duenas Carrera, Carlos Duarte Cano, Peter Vanlandshoot, Luis Herrera Martinez